Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies.

MLA

Wild, Sophia A., et al. “Clonal Transcriptomics Identifies Mechanisms of Chemoresistance and Empowers Rational Design of Combination Therapies.” ELife, Dec. 2022, pp. 1–36. EBSCOhost, https://doi.org/10.7554/eLife.80981.

APA

Wild, S. A., Cannell, I. G., Nicholls, A., Kania, K., Bressan, D., Hannon, G. J., & Sawicka, K. (2022). Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. ELife, 1–36. https://doi.org/10.7554/eLife.80981

Chicago

Wild, Sophia A., Ian G. Cannell, Ashley Nicholls, Katarzyna Kania, Dario Bressan, Gregory J. Hannon, and Kirsty Sawicka. 2022. “Clonal Transcriptomics Identifies Mechanisms of Chemoresistance and Empowers Rational Design of Combination Therapies.” ELife, December, 1–36. doi:10.7554/eLife.80981.